The purpose of this article is to highlight the potential challenges associated with the Prostate Imaging Reporting and Data System, version 2 (PI-RADS v2), and to offer, when possible, suggestions and ideas for improvement.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PI-RADS v2 offers clear improvements to its earlier version and will greatly benefit the prostate MRI community. Nonetheless, caution remains on the basis of early user experience, and potential ambiguities and gaps of PI-RADS v2 are noted. Continued data-driven clarification and refinement of the guidelines will be invaluable for PI-RADS v2 to achieve its goal of improving patient care.
AJR. American journal of roentgenology. 2016 Feb 25 [Epub ahead of print]
Andrew B Rosenkrantz, Aytekin Oto, Baris Turkbey, Antonio C Westphalen
1 Department of Radiology, Center for Biomedical Imaging, New York University School of Medicine, New York University Langone Medical Center, 660 First Ave, 3rd Fl, New York, NY 10016., 2 Department of Radiology, University of Chicago, Chicago, IL., 3 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD., 4 Department of Radiology, University of California, San Francisco, San Francisco, CA.